

Synthetic Antimicrobial Peptides for Selective and Potent Malaria Treatment

(No. T4-2408)

Principal investigator

Neta Regev Rudzki

Faculty of Biochemistry Department of Biomolecular Sciences

Overview

Malaria remains a major global health challenge, with increasing resistance to current drugs and limited treatment options that selectively target infected red blood cells. This technology introduces synthetic antimicrobial peptides (AMPs) composed of leucine and lysine in D- and L- configurations. These peptides selectively penetrate and disrupt Plasmodium falciparum-infected red blood cells (Pf-iRBCs) without affecting healthy cells, offering a highly specific, non-toxic, and resistance-resilient therapeutic approach.

Applications

Applications

- Standalone treatment for malaria caused by Plasmodium falciparum
- Combination therapy with existing antimalarial drugs (e.g., artemisinin, chloroquine)
- Reduces transmission by targeting the P. falciparum membrane via a non-receptor mechanism with low resistance risk

Differentiation

- Selectively targets infected red blood cells while sparing naÃ⁻ve RBCs
- Minimal hemolysis, with a promising IC50 in unpublished results
- Cholesterol-dependent, non-receptor-mediated mechanism ensures high specificity for Pf-iRBCs and lowers the risk of resistance development
- Compatible with drug conjugation for targeted delivery.

Development Stage

Demonstrated potent in vitro activity against P.falciparum with clear selectivity and a favorable safety profile. Mechanism of action confirmed via flow cytometry, AFM, and biophysical assays. The initial IP was filed; further validation is underway for clinical translation.

References

Kiper E, [1] Ben Hur D, et al. *J Biol Chem*. 2025;301(4):108298. Yeda Research & Development Co. Ltd, 95 Rehovot 7610002, Israel Tel. +972.8.9470617 Anti-*Pf* AMPs selectively bind to *Pf*-iRBCs, with maximal binding appearing at the late trophozoite–schizont stage, 8 Hours post-treatment.

Â

